Global Peptic Ulcer Drugs Market Size, Share, Trends & Forecast

The Global Peptic Ulcer Drugs Market is expanding as the prevalence of Helicobacter pylori infection, aging populations, and NSAID-related ulcer cases sustain demand for gastrointestinal therapies. The market was valued at USD 5.71 billion in 2025 and is projected to reach USD 9.74 billion by 2035, at a 5.48% CAGR. Growing screening programs, improved healthcare access, and advances in acid-suppression therapies are shaping market development.

Pharmaceutical innovation is increasingly focused on potassium-competitive acid blockers (PCABs), which offer a newer approach to acid suppression. While proton pump inhibitors (PPIs) accounted for 54.7% of market revenue in 2024, PCABs are projected to record the fastest growth at a 9.83% CAGR through 2035. These developments are encouraging manufacturers to expand next-generation treatment portfolios.

Gastric ulcers represented the largest clinical indication with a 43.0% share in 2024. H. pylori eradication remains an important treatment requirement, while stress-related mucosal damage is emerging as a faster-growing indication as critical-care admissions and prophylaxis practices increase. Antibiotic resistance is also encouraging interest in alternative and combination treatment regimens.

Hospital pharmacies accounted for 46.8% of distribution revenue in 2024, supported by inpatient prescribing and formulary-based purchasing. North America held the largest regional share at 32.3%, while Asia-Pacific is projected to record the fastest regional CAGR of 5.58% as screening initiatives and healthcare access expand. Digital pharmacies are also creating new distribution opportunities.

Future opportunities may arise from next-generation PCABs, microbiome-guided treatment, digital adherence platforms, and personalized H. pylori therapy. Online pharmacies and e-commerce are projected to grow at an 11.50% CAGR through 2035, while improved diagnostic tools could help physicians select more targeted treatment regimens. These developments could make peptic ulcer management increasingly personalized, connected, and digitally supported.